Editorials

Low dose CT screening for lung cancer

BMJ 2017; 359 doi: https://doi.org/10.1136/bmj.j5742 (Published 28 December 2017) Cite this as: BMJ 2017;359:j5742
  1. David R Baldwin, consultant respiratory physician1,
  2. Kevin ten Haaf, researcher2,
  3. Janette Rawlinson, consumer member, NCRI Lung Cancer Clinical Studies Group3,
  4. Matthew E J Callister, consultant respiratory physician4
  1. 1University of Nottingham Respiratory Medicine Unit, Nottingham University Hospitals, Nottingham, UK
  2. 2Erasmus MC Department of Public Health, Rotterdam, Netherlands
  3. 3Macmillan and Roy Castle Lung Cancer Foundation, Sandwell, UK
  4. 4St James’s University Hospital, Leeds, UK
  1. Correspondence to: D R Baldwin David.baldwin{at}nuh.nhs.uk

Pilots in car parks take the UK one step closer to national screening

The head of NHS England, Simon Stevens, recently announced plans to expand pilot schemes offering lung cancer screening in supermarket car parks.1 This has prompted inevitable questions about national screening for a cancer that causes more deaths in developed countries than breast and bowel cancers combined.

Lung cancer is curable if found at an early stage, but two thirds of people present with advanced disease, when survival is short and cure uncommon. Established screening programmes for breast and bowel cancer exist in many developed nations, but only the US and Canada have approved national screening for lung cancer with low dose computed tomography (CT), based primarily on findings from the US National Lung Screening Trial.2

The trial reported reductions in mortality from both lung cancer and all causes (20% and 6.7% respectively) after annual CT for three years compared with annual chest radiography. The final results from the …

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription